Positive suggestions about the anti-HBc positive donor

Gut

Volumn 50, Issue 1, 2002, Pages 7-8

  Mutimer, D ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

GEOGRAPHIC PATHOLOGY; GRAFT FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNITY; IMMUNOPROPHYLAXIS; LIVER TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL; SHORT SURVEY;

HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER TRANSPLANTATION; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 0036136113     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.50.1.7     Document Type: Short Survey

References (9)

1. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors
2. The risk of transmission of hepatitis B from HBsAg (-), HBcAb (+), HBIgM (-) organ donors
3. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database
4. De novo hepatitis B infection acquired during liver transplantation
5. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants
6. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation
7. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivizy in the donor population
8. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors
9. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy